Zhang W, Liu H, Zhang D, Yi Y, Tao L, Zhu Y
Elife. 2025; 13.
PMID: 39886919
PMC: 11785375.
DOI: 10.7554/eLife.96798.
Huang H, Colasanti O, Li T, Lohmann V
J Virol. 2025; 99(2):e0226424.
PMID: 39853114
PMC: 11852894.
DOI: 10.1128/jvi.02264-24.
He F, Du W, Liu Y, Ling Y, Xu M, Liu J
Redox Biol. 2025; 80:103488.
PMID: 39778469
PMC: 11763583.
DOI: 10.1016/j.redox.2025.103488.
Hong Y, Chen X, Yuan H, Huang Z, Tao S, Xie F
BMC Gastroenterol. 2024; 24(1):439.
PMID: 39609681
PMC: 11603918.
DOI: 10.1186/s12876-024-03525-z.
Cao Y, Yi Y, Han C, Shi B
Front Immunol. 2024; 15:1476030.
PMID: 39493763
PMC: 11530992.
DOI: 10.3389/fimmu.2024.1476030.
Clinical and preclinical studies of mesenchymal stem cells to alleviate peritoneal fibrosis.
Zheng L, Chen W, Yao K, Xie Y, Liao C, Zhou T
Stem Cell Res Ther. 2024; 15(1):237.
PMID: 39080683
PMC: 11290310.
DOI: 10.1186/s13287-024-03849-3.
NF-κB role on tumor proliferation, migration, invasion and immune escape.
Khan A, Zhang Y, Ma N, Shi J, Hou Y
Cancer Gene Ther. 2024; 31(11):1599-1610.
PMID: 39033218
DOI: 10.1038/s41417-024-00811-6.
NEMO/NF-κB signaling functions as a double-edged sword in PanIN formation versus progression to pancreatic cancer.
Tsesmelis M, Buttner U, Gerstenlauer M, Manfras U, Tsesmelis K, Du Z
Mol Cancer. 2024; 23(1):103.
PMID: 38755681
PMC: 11097402.
DOI: 10.1186/s12943-024-01989-x.
NFKBIZ regulates NFκB signaling pathway to mediate tumorigenesis and metastasis of hepatocellular carcinoma by direct interaction with TRIM16.
Guo D, Zhang M, Wei T, Zhang X, Shi X, Tang H
Cell Mol Life Sci. 2024; 81(1):167.
PMID: 38581570
PMC: 10998794.
DOI: 10.1007/s00018-024-05182-7.
Dual regulation of NEMO by Nrf2 and miR-125a inhibits ferroptosis and protects liver from endoplasmic reticulum stress-induced injury.
Tak J, Joo M, Kim Y, Park H, Lee C, Park G
Theranostics. 2024; 14(5):1841-1859.
PMID: 38505605
PMC: 10945339.
DOI: 10.7150/thno.89703.
NF-κB: Governing Macrophages in Cancer.
Cornice J, Verzella D, Arboretto P, Vecchiotti D, Capece D, Zazzeroni F
Genes (Basel). 2024; 15(2).
PMID: 38397187
PMC: 10888451.
DOI: 10.3390/genes15020197.
Implications of neonatal absence of innate immune mediated NFκB/AP1 signaling in the murine liver.
Grayck M, McCarthy W, Solar M, Balasubramaniyan N, Zheng L, Orlicky D
Pediatr Res. 2024; 95(7):1791-1802.
PMID: 38396130
DOI: 10.1038/s41390-024-03071-0.
IKKε and TBK1 prevent RIPK1 dependent and independent inflammation.
Eren R, Kaya G, Schwarzer R, Pasparakis M
Nat Commun. 2024; 15(1):130.
PMID: 38167258
PMC: 10761900.
DOI: 10.1038/s41467-023-44372-y.
Anti-NF-κB peptide derived from nuclear acidic protein attenuates ovariectomy-induced osteoporosis in mice.
Takami K, Okamoto K, Etani Y, Hirao M, Miyama A, Okamura G
JCI Insight. 2023; 8(22).
PMID: 37991021
PMC: 10721323.
DOI: 10.1172/jci.insight.171962.
Regulation of apoptosis by ubiquitination in liver cancer.
Li Y, Zhu J, Yu Z, Zhai F, Li H, Jin X
Am J Cancer Res. 2023; 13(10):4832-4871.
PMID: 37970337
PMC: 10636691.
A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease.
Hammoutene A, Laouirem S, Albuquerque M, Colnot N, Brzustowski A, Valla D
JHEP Rep. 2023; 5(10):100845.
PMID: 37663119
PMC: 10472315.
DOI: 10.1016/j.jhepr.2023.100845.
Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma.
Talamantes S, Lisjak M, Gilglioni E, Llamoza-Torres C, Ramos-Molina B, Gurzov E
JHEP Rep. 2023; 5(9):100811.
PMID: 37575883
PMC: 10413159.
DOI: 10.1016/j.jhepr.2023.100811.
Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis.
Gui W, Hole M, Molinaro A, Edlund K, Jorgensen K, Su H
Nat Commun. 2023; 14(1):3304.
PMID: 37280200
PMC: 10244448.
DOI: 10.1038/s41467-023-38840-8.
The Expressions of NF-κB, COX-2, Sp1, and c-Jun in Pancreatic Ductal Adenocarcinoma and Their Associations with Patient Survival.
Renaldi K, Simadibrata M, Rahadiani N, Handjari D, Harahap A, Harimurti K
Pathophysiology. 2023; 30(2):92-109.
PMID: 37092523
PMC: 10123625.
DOI: 10.3390/pathophysiology30020009.
A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-B pathway.
Yoon S, Hong H, Lim H, Choi J, Choi Y, Seo S
Acta Pharm Sin B. 2023; 13(3):1093-1109.
PMID: 36970199
PMC: 10031381.
DOI: 10.1016/j.apsb.2022.12.001.